Home > Journals > Minerva Chirurgica > Past Issues > Articles online first > Minerva Chirurgica 2020 Aug 06

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Minerva Chirurgica 2020 Aug 06

DOI: 10.23736/S0026-4733.20.08436-9

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

The actual management of colorectal liver metastases

Leticia PÉREZ-SANTIAGO 1, Dimitri DORCARATTO 1 , Marina GARCÉS-ALBIR 1, Elena MUÑOZ-FORNER 1, Marisol HUERTA ÁLVARO 2, Susana ROSELLÓ KERANËN 2, Luis SABATER 1

1 Department of Surgery, Liver, Biliary and Pancreatic Unit, Hospital Clínico, University of Valencia, Biomedical Research Institute (INCLIVA), Valencia, Spain; 2 Department of Medical Oncology, Hospital Clínico, University of Valencia, Biomedical Research Institute (INCLIVA), Valencia, Spain


PDF


Colorectal cancer is one of the most frequent cancers in the world and between 50% and 60% of patients will develop colorectal liver metastases (CRLM) during the course of the disease. There have been great improvements in the management of CRLM during the last decades. The combination of modern chemotherapeutic and biological systemic treatments with aggressive surgical resection strategies is currently the base for the treatment of patients considered unresectable until few years ago. Furthermore, several new treatments for the local control of CRLM have been developed and are now part of the arsenal of multidisciplinary teams for the treatment of these complex patients. The aim of this review is to summarize and update the management of CRLM, its controversies and relevant evidence.


KEY WORDS: Colorectal cancer; Liver metastases; Chemotherapy; Multidisciplinary approach; Synchronous disease

top of page